NEW YORK (GenomeWeb) – CollabRx and Medytox today announced they have reached a definitive merger agreement. 

Under the terms of the deal, CollabRx shareholders will own a 10 percent stake in the combined company, of which it will operate as a wholly owned subsidiary. Medytox shareholders will own the remaining 90 percent. Further terms of the deal were not disclosed. 

The companies previously entered into a non-binding letter of intent to negotiate a merger.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.